[Department of Error] Department of Error

September 4, 2017

The Lancet 390, 10097 (2017)

Balar AV, Galsky MD, Rosenberg JE, et al, for the IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017; 389: 67–76—In figure 3 of this Article (published Online First on Dec 7, 2016), all patients should be grey in the key and IC0/1 should be green. These corrections have been made to the online version as of Aug 11, 2017.